Please use this identifier to cite or link to this item: https://accedacris.ulpgc.es/handle/10553/50548
DC FieldValueLanguage
dc.contributor.authorRomagnoli, Romeoen_US
dc.contributor.authorBaraldi, Pier Giovannien_US
dc.contributor.authorSalvador, Maria Kimatraien_US
dc.contributor.authorCamacho, M. Encarnacionen_US
dc.contributor.authorBalzarini, Janen_US
dc.contributor.authorBermejo, Jaimeen_US
dc.contributor.authorEstévez, Franciscoen_US
dc.contributor.otherCamacho, M. Encarnacion-
dc.contributor.otherBaraldi, Pier Giovanni-
dc.contributor.otherRomagnoli, Romeo-
dc.contributor.otherEstevez, Francisco-
dc.date.accessioned2018-11-24T16:54:20Z-
dc.date.available2018-11-24T16:54:20Z-
dc.date.issued2013en_US
dc.identifier.issn0223-5234en_US
dc.identifier.urihttps://accedacris.ulpgc.es/handle/10553/50548-
dc.description.abstractHybridization of two different bioactive molecules with different mechanism of action is one of the methods that are being adopted to treat cancer. Molecules bearing a thiazolidine-2,4-dione scaffold have been recognized as antineoplastic agents with a broad spectrum of activity against many cancer cell lines. In this manuscript we have described the synthesis and biological evaluation of two series of N-3-substituted-5-arylidene thiazolidine-2,4-diones, bearing the alpha-bromoacryloylamido moiety at the para- or meta-position on the phenyl of the arylidene portion. We have observed that selected compounds 5a, 5c and 5g suppress proliferation of human myeloid leukaemia HL-60 and U937 cells by triggering morphological changes and internucleosomal DNA fragmentation, which are well-known features of apoptosis. Finally, our results indicated that the investigated compounds induced apoptotic cell death through a mechanism that involved activation of multiple caspases and was also associated with the release of cytochrome c from the mitochondria.en_US
dc.languageengen_US
dc.relationEvaluación de Potenciales Compuestos Antileucémicos.en_US
dc.relation.ispartofEuropean Journal of Medicinal Chemistryen_US
dc.sourceEuropean Journal of Medicinal Chemistry[ISSN 0223-5234],v. 63, p. 544-557en_US
dc.subject32 Ciencias médicasen_US
dc.subject320713 Oncologíaen_US
dc.subject.otherHuman Leukemia-Cellsen_US
dc.subject.otherCytochrome-Cen_US
dc.subject.otherCancer Cellsen_US
dc.subject.otherCaspasesen_US
dc.subject.otherDeathen_US
dc.subject.otherBrostallicinen_US
dc.subject.otherDerivativesen_US
dc.subject.otherInhibitionen_US
dc.subject.otherMechanismsen_US
dc.subject.otherApoptosisen_US
dc.titleAnticancer activity of novel hybrid molecules containing 5-benzylidene thiazolidine-2,4-dioneen_US
dc.typeinfo:eu-repo/semantics/Articleen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.ejmech.2013.02.030en_US
dc.identifier.scopus84875332058-
dc.identifier.isi000322855400052-
dcterms.isPartOfEuropean Journal Of Medicinal Chemistry-
dcterms.sourceEuropean Journal Of Medicinal Chemistry[ISSN 0223-5234],v. 63, p. 544-557-
dc.contributor.authorscopusid7101729609-
dc.contributor.authorscopusid7101681318-
dc.contributor.authorscopusid54684944400-
dc.contributor.authorscopusid7102602358-
dc.contributor.authorscopusid36049696300-
dc.contributor.authorscopusid7101636723-
dc.contributor.authorscopusid7003810011-
dc.description.lastpage557en_US
dc.description.firstpage544en_US
dc.relation.volume63en_US
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.identifier.wosWOS:000322855400052-
dc.contributor.daisngid32727-
dc.contributor.daisngid38403-
dc.contributor.daisngid2498213-
dc.contributor.daisngid1068655-
dc.contributor.daisngid233-
dc.contributor.daisngid5695465-
dc.contributor.daisngid384944-
dc.identifier.investigatorRIDG-7916-2015-
dc.identifier.investigatorRIDB-7933-2017-
dc.identifier.investigatorRIDG-9887-2015-
dc.identifier.investigatorRIDK-5125-2014-
dc.description.numberofpages14en_US
dc.utils.revisionen_US
dc.contributor.wosstandardWOS:Romagnoli, R-
dc.contributor.wosstandardWOS:Baraldi, PG-
dc.contributor.wosstandardWOS:Salvador, MK-
dc.contributor.wosstandardWOS:Camacho, ME-
dc.contributor.wosstandardWOS:Balzarini, J-
dc.contributor.wosstandardWOS:Bermejo, J-
dc.contributor.wosstandardWOS:Estevez, F-
dc.date.coverdateMarzo 2013en_US
dc.identifier.ulpgcen_US
dc.contributor.buulpgcBU-MEDen_US
dc.description.sjr1,209-
dc.description.jcr3,432-
dc.description.sjrqQ1-
dc.description.jcrqQ1-
dc.description.scieSCIE-
item.fulltextSin texto completo-
item.grantfulltextnone-
crisitem.project.principalinvestigatorEstévez Rosas, Francisco Jesús-
crisitem.author.deptGIR IUIBS: Bioquímica-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptDepartamento de Bioquímica y Biología Molecular, Fisiología, Genética e Inmunología-
crisitem.author.orcid0000-0002-9728-2774-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.fullNameEstévez Rosas, Francisco Jesús-
Appears in Collections:Artículos
Show simple item record

SCOPUSTM   
Citations

62
checked on Mar 30, 2025

WEB OF SCIENCETM
Citations

62
checked on Mar 30, 2025

Page view(s)

96
checked on Jan 18, 2025

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.